PL395469A1 - Pochodne indoloamin do leczenia chorób osrodkowego ukladu nerwowego - Google Patents

Pochodne indoloamin do leczenia chorób osrodkowego ukladu nerwowego

Info

Publication number
PL395469A1
PL395469A1 PL395469A PL39546911A PL395469A1 PL 395469 A1 PL395469 A1 PL 395469A1 PL 395469 A PL395469 A PL 395469A PL 39546911 A PL39546911 A PL 39546911A PL 395469 A1 PL395469 A1 PL 395469A1
Authority
PL
Poland
Prior art keywords
indolamines
diseases
derivatives
treatment
nervous system
Prior art date
Application number
PL395469A
Other languages
English (en)
Inventor
Marcin Kolaczkowski
Monika Jagodzińska
Adam Bucki
Maciej Pawłowski
Grzegorz Kazek
Marek Bednarski
Anna Wesołowska
Original Assignee
Adamed Spólka Z Ograniczona Odpowiedzialnoscia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adamed Spólka Z Ograniczona Odpowiedzialnoscia filed Critical Adamed Spólka Z Ograniczona Odpowiedzialnoscia
Priority to PL395469A priority Critical patent/PL395469A1/pl
Priority to US14/125,750 priority patent/US20140121216A1/en
Priority to EP12762390.8A priority patent/EP2726457A1/en
Priority to MX2013014661A priority patent/MX2013014661A/es
Priority to KR1020147000780A priority patent/KR20140040218A/ko
Priority to CA2838314A priority patent/CA2838314A1/en
Priority to BR112013033603A priority patent/BR112013033603A2/pt
Priority to JP2014518038A priority patent/JP2014518257A/ja
Priority to AU2012277358A priority patent/AU2012277358A1/en
Priority to PCT/IB2012/053309 priority patent/WO2013001499A1/en
Priority to CN201280031813.6A priority patent/CN103649048A/zh
Priority to EA201490182A priority patent/EA201490182A1/ru
Publication of PL395469A1 publication Critical patent/PL395469A1/pl
Priority to IL229791A priority patent/IL229791A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL395469A 2011-06-29 2011-06-29 Pochodne indoloamin do leczenia chorób osrodkowego ukladu nerwowego PL395469A1 (pl)

Priority Applications (13)

Application Number Priority Date Filing Date Title
PL395469A PL395469A1 (pl) 2011-06-29 2011-06-29 Pochodne indoloamin do leczenia chorób osrodkowego ukladu nerwowego
CA2838314A CA2838314A1 (en) 2011-06-29 2012-06-28 Indoleamine derivatives for the treatment of central nervous system diseases
EP12762390.8A EP2726457A1 (en) 2011-06-29 2012-06-28 Indoleamine derivatives for the treatment of central nervous system diseases
MX2013014661A MX2013014661A (es) 2011-06-29 2012-06-28 Derivados de indolamina para el tratamiento de enfermedades del sistema nervioso central.
KR1020147000780A KR20140040218A (ko) 2011-06-29 2012-06-28 중추 신경계 질환의 치료를 위한 인돌아민 유도체
US14/125,750 US20140121216A1 (en) 2011-06-29 2012-06-28 Indoleamine derivatives for the treatment of central nervous system diseases
BR112013033603A BR112013033603A2 (pt) 2011-06-29 2012-06-28 derivados de indolamina para o tratamento de enfermidades do sistema nervoso
JP2014518038A JP2014518257A (ja) 2011-06-29 2012-06-28 中枢神経系疾患の処置のためのインドールアミン誘導体
AU2012277358A AU2012277358A1 (en) 2011-06-29 2012-06-28 Indoleamine derivatives for the treatment of central nervous system diseases
PCT/IB2012/053309 WO2013001499A1 (en) 2011-06-29 2012-06-28 Indoleamine derivatives for the treatment of central nervous system diseases
CN201280031813.6A CN103649048A (zh) 2011-06-29 2012-06-28 用于治疗中枢神经系统疾病的吲哚胺衍生物
EA201490182A EA201490182A1 (ru) 2011-06-29 2012-06-28 Индоламинные производные для лечения заболеваний центральной нервной системы
IL229791A IL229791A0 (en) 2011-06-29 2013-12-04 Indoleamine derivatives for the treatment of diseases of the central nervous system

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL395469A PL395469A1 (pl) 2011-06-29 2011-06-29 Pochodne indoloamin do leczenia chorób osrodkowego ukladu nerwowego

Publications (1)

Publication Number Publication Date
PL395469A1 true PL395469A1 (pl) 2013-01-07

Family

ID=46889380

Family Applications (1)

Application Number Title Priority Date Filing Date
PL395469A PL395469A1 (pl) 2011-06-29 2011-06-29 Pochodne indoloamin do leczenia chorób osrodkowego ukladu nerwowego

Country Status (13)

Country Link
US (1) US20140121216A1 (pl)
EP (1) EP2726457A1 (pl)
JP (1) JP2014518257A (pl)
KR (1) KR20140040218A (pl)
CN (1) CN103649048A (pl)
AU (1) AU2012277358A1 (pl)
BR (1) BR112013033603A2 (pl)
CA (1) CA2838314A1 (pl)
EA (1) EA201490182A1 (pl)
IL (1) IL229791A0 (pl)
MX (1) MX2013014661A (pl)
PL (1) PL395469A1 (pl)
WO (1) WO2013001499A1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106749219A (zh) * 2015-11-20 2017-05-31 江苏恩华药业股份有限公司 一种内酰胺类衍生物及其应用
EP3530651A1 (en) * 2018-02-21 2019-08-28 Adamed sp. z o.o. Indole and benzimidazole derivatives as dual 5-ht2a and 5-ht6 receptor antagonists
CN116554145B (zh) * 2022-01-29 2025-06-03 江苏恩华药业股份有限公司 芳烷基-4-(1h)吲哚基哌嗪衍生物、其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996003400A1 (en) * 1994-07-26 1996-02-08 Pfizer Inc. 4-indole derivatives as serotonin agonists and antagonists
ES2271967T3 (es) 1996-03-29 2007-04-16 Duphar International Research B.V Compuestos de piperazina y piperidina.
ZA9711376B (en) 1996-12-20 1998-07-21 Lundbeck & Co As H Indole or dihydroindole derivatives
ATE252575T1 (de) 1997-07-25 2003-11-15 Lundbeck & Co As H Indole und 2,3-dihydroindolderivate, ihre herstellung und verwendung
EP0900792B1 (en) 1997-09-02 2003-10-29 Duphar International Research B.V Piperazine and piperidine derivatives as 5-HT1A and dopamine D2-receptor (ant)agonists
AU3667899A (en) 1998-04-29 1999-11-16 American Home Products Corporation Antipsychotic indolyl derivatives
AR027134A1 (es) 1999-12-30 2003-03-12 Lundbeck & Co As H Derivados de indol.
KR100823908B1 (ko) 2000-10-20 2008-04-21 바이오비트럼 에이비(피유비엘) 2-, 3-, 4-, 또는 5-치환-ｎ1-(벤젠술포닐)인돌 및 이의치료 용도
EP2298738B1 (en) * 2000-11-02 2012-09-19 Wyeth LLC 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
GB0227240D0 (en) 2002-11-21 2002-12-31 Glaxo Group Ltd Compounds
RU2497819C2 (ru) 2007-05-21 2013-11-10 Ривайва Фармасьютикалс, Инк. Композиции, синтез и способы применения атипичных нейролептиков на основе хинолина

Also Published As

Publication number Publication date
BR112013033603A2 (pt) 2016-09-06
EA201490182A1 (ru) 2014-04-30
EP2726457A1 (en) 2014-05-07
IL229791A0 (en) 2014-03-06
CN103649048A (zh) 2014-03-19
AU2012277358A1 (en) 2014-01-23
KR20140040218A (ko) 2014-04-02
MX2013014661A (es) 2014-03-27
WO2013001499A1 (en) 2013-01-03
US20140121216A1 (en) 2014-05-01
JP2014518257A (ja) 2014-07-28
CA2838314A1 (en) 2013-01-03

Similar Documents

Publication Publication Date Title
ZA201402424B (en) 1- arylcarbonyl -4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases
ZA201404787B (en) Substituted 4-phenyl-pyridines for the treatment of nk-1 receptor related diseases
IL221517A (en) A device for treating headaches
GB2503852B (en) Compounds for the treatment of neuropsychiatric disorders
ZA201309557B (en) Methods of treatment for retinal diseases
ZA201501390B (en) Compounds for the treatment of mtor pathway related diseases
IL229705A0 (en) Methods for the treatment or prevention of neurological diseases
PL392436A1 (pl) Pochodne arylosulfonamidów do leczenia chorób odśrodkowego układu nerwowego
PT2691103T (pt) Método para o tratamento de distúrbios da pele
IL239273A0 (en) A method of treating diseases
IL275636A (en) Medical combination for cancer treatment
ZA201400636B (en) Sulphonamide derivatives of alicyclic amines for the treatment of central nervous system diseases
IL229791A0 (en) Indoleamine derivatives for the treatment of diseases of the central nervous system
IL234796B (en) Compounds for the treatment of diseases related to ischemia-reperfusion
HK40043513B (en) Interval therapy for the treatment of eye diseases
HUP1100723A2 (en) Use of estrogen derivatives for preparing medicament for the treatment of psychiatric diseases
IL228973A0 (en) Oxymetazoline for the treatment of anorectal disorders
HK1193343A (en) Methods for treating diseases of the retina
HK1193358A (zh) 一种治疗疾病或中枢神经系统病症的方法
AU2011900737A0 (en) Methods of Treating a Disease or Condition of the Central Nervous System

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)